Ignite Creation Date:
2024-05-06 @ 9:55 AM
Last Modification Date:
2024-10-26 @ 12:22 PM
Study NCT ID:
NCT03113760
Status:
COMPLETED
Last Update Posted:
2024-02-02
First Post:
2017-02-28
Brief Title:
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
Sponsor:
AB2 Bio Ltd
Organization:
AB2 Bio Ltd
Organization Data
Organization:
AB2 Bio Ltd
Class:
INDUSTRY
Study ID:
NLRC4XIAP2016001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
AB2 Bio Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None